Discovery of a novel potentially transforming somatic mutation in CSF2RB gene in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The colony stimulating factor 2 receptor subunit beta (CSF2RB) is crucial for cytokine signaling, and its mutations can cause ligand independence.
• While germline CSF2RB mutations have been linked to leukemia, oncogenic somatic CSF2RB mutations in breast cancer remain largely uncharacterized.

Purpose of the Study:

• To identify novel somatic mutations in CSF2RB in breast cancer.
• To investigate the functional and clinical significance of identified CSF2RB mutations in breast cancer.

Main Methods:

• Exome sequencing of breast tumor tissue and peripheral blood mononuclear cells (PBMCs) to identify somatic mutations.
• Functional assays and immunoblot analysis to assess the signaling pathways affected by mutant CSF2RB.
• Screening of small molecule kinase inhibitors against cancer cell lines harboring the mutation.

Main Results:

• A novel somatic mutation, S230I, in the CSF2RB gene was discovered in a breast cancer patient and the derived KAIMRC1 cell line.
• KAIMRC1 cells with the S230I mutation exhibit ligand-independent survival and proliferation, signaling through JAK2/STAT and PI3K/mTOR pathways.
• Potent JAK2 inhibitors were identified as effective against KAIMRC1 cells, indicating the mutation's actionable nature.

Conclusions:

• The study reports the first identification of a potentially transforming and oncogenic somatic CSF2RB mutation (S230I) in breast cancer.
• This mutation activates key oncogenic signaling pathways, making it a potential therapeutic target for breast cancer treatment.
• The findings highlight the actionable nature of the S230I CSF2RB mutation and suggest a new avenue for breast cancer therapy development.